An interventional study of Physical activity and Cognitive stimulation in Aging, Age-Related Cognitive Decline and Sarcopenia, sponsored by Istituto di Neuroscienze Consiglio Nazionale delle Ricerche. Completed at 2 sites in Italy. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by Istituto di Neuroscienze Consiglio Nazionale delle Ricerche · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Sarcopenia with a site in Italy — 29 open to participants now, 32 under way, 1 of them phase 3. Sarcopenia · Italy.
Among the 70 studies in Sarcopenia with a site in Italy, this one is the 21st largest by enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2025, is one of 35 with no phase, and was the 51st registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →29 of the 70 studies in Sarcopenia with a site in Italy are open now. Recruiting first, the newest first:
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · Sites in Italy
Ages 50+ · Healthy volunteers
Fondazione Don Carlo Gnocchi ETS · Sites in Italy
Ages 30–75
Lionhealth Srl Società Benefit · Sites in Italy
Ages 18–65
Istituto di Neuroscienze Consiglio Nazionale delle Ricerche · Sites in Italy, Austria
Ages 35+ · Women only
Universita di Verona · Sites in Italy
Ages 65–85
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 60 across 860 interventional studies indexed under Sarcopenia.
Median enrollment 100 across the 39 interventional studies, 160 across the 31 observational. Of the 25 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 70 have an industry lead sponsor. The 10 most frequent:
Istituto di Neuroscienze Consiglio Nazionale delle Ricerche is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Istituto di Neuroscienze Consiglio Nazionale delle Ricerche has 2 studies filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
5 of the studies in Sarcopenia with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07433946Lionhealth Srl Società BenefitPartial Enteral Nutrition to Prevent Weight Loss and Sarcopenia in IBD Patients at Nutritional Risk - SIMBA | 2026-12-15 |
| NCT04730622Istituto Ortopedico RizzoliStudy of Parameters of Osteosarcopenia in Patients With Hip Fracture | 2026-12-31 |
| NCT07692308I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioMorphological and Functional Biomarkers of Skeletal Muscle Adaptations in Sarcopenia | 2027-06-03 |
| NCT07511413Fondazione del Piemonte per l'OncologiaGALENOS 1 in Head and Neck, Lung, and Rectal Cancer Patients | 2027-08-30 |
| NCT07883161Fondazione Policlinico Universitario Agostino Gemelli IRCCSTargeted Nutritional Intervention (HMB, Arginine, Glutamine) in Patients With Pancreatic Cancer | 2027-09-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 70 studies in Sarcopenia with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The "Multidomain Interventions to improve the COgnitive and fUNctional well-being of elderly individuals in residential sTructures" (I-COUNT) study aims to test the feasibility and the effectiveness of a multidisciplinary intervention among elderly individuals living in long term care facilities (LTCFs). The intervention will include selected physical and cognitive training activities administered and monitored by new technologies, a dietary intervention including also functional foods, and the administration of vaccines according to the National plan. The multidomain intervention will last 6 months and will be compared with the standard care adopted in the same LTCFs.
I-COUNT is a randomized controlled trial that will be conducted among residents in two residential facilities in Italy. Sixty participants will be enrolled in each residential facility (30 control group, 30 intervention group).
During the first phase of the study, eligible residents of the participating LTCFs will be enrolled according to the following inclusion and exclusion criteria. Baseline evaluations will be based on a geriatric multidimensional assessment including body composition assessment, physical performance assessment, Mediterranean diet adherence assessment, psychological and neuropsychological evaluations. Blood, plasma, stool and urine samples will also be collected.
In phase two, which will last 6 months, participants in the intervention group will undergo the planned interventions, while controls will be asked to continue with their usual activities. The physical activity will consist of three 40-minutes sessions per week, with personalized exercises prescribed by a physiotherapist and performed in small groups, under supervision. The cognitive training will be based on the computer program Remote stimulation for Cognitive Decline (RECODE), developed by the Department of General Psychology, University of the Padua, with two sessions per week. The intervention group will also receive functional foods (sourdough bread enriched with a vegetable matrix rich in polyphenols (olive leaves) and vegetables enriched with probiotics (artichokes)).
In phase 3, participants will be reassessed at 3 months (gut microbiota only), and 6 and 9 months after the start of the intervention (selected biomarkers, nutritional and anthropometric status, psychological health, physical performance tests, cognitive function, acceptability of the technological monitoring and interventions).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The 6-month intervention will include supervised physical exercises (each session will last 40 minutes, three times a week, with accelerometers and smartwatches to monitor the physical activity performed), and cognitive stimulation (delivered by neuropsychologists twice a week for 30 minutes, in small groups). Participants in the intervention group will be advised to follow a Mediterranean diet, will receive functional foods (sourdough bread fortified with vegetable matrix rich in polyphenols and probiotic artichokes), and will be offered to receive appropriate vaccinations according to the national vaccination calendar.
Other: Physical activity · Other: Cognitive stimulation · Other: Nutritional Intervention · Other: Vaccinations
Subjects in the control group will receive general information on healthy lifestyles and health, including risk factors.
Appropriate exercises for supervised small group sessions will be prescribed by a physiotherapist or expert in exercise science. Each session will last approximately 40 minutes, three times a week, and will be based on the international guidelines for physical exercise in the elderly population, and the VIVIFRAIL Multicomponent Physical Exercise Program to Prevent Frailty and the Risk of Falls. Accelerometers and other wearable sensors (smartwatches) will be used to monitor the physical activity performed.
Cognitive stimulation will be delivered by expert neuropsychologists twice a week (48 sessions in total) for approximately 30 minutes. Residents will be divided into small groups (3-5 people) of similar cognitive level, and the intervention will be delivered using a computerized tool (REmote stimulation for COgnitive DEcline (RECODE) developed by researchers at the University of Padova with the aim of stimulating different domains (i.e., attention, working memory, visual memory, language, orientation and executive functions) through exercises of increasing difficulty.
Participants in the intervention group will be advised to follow a Mediterranean diet and will also receive functional foods; in particular, they will be offered 80 g/day of sourdough bread fortified with vegetable matrix rich in polyphenols (e.g., olive leaves) and 100 g/day of probiotic artichokes on alternate days.
Participants in the intervention group will be offered to receive appropriate vaccinations according to the national vaccination calendar. Vaccine doses will be provided by the Department of Preventive Medicine, Vaccine Office, National Health Service, on prescription from the general practitioners.
Effect of the multidomain intervention on the gut microbiota composition
Changes in gut microbiota biodiversity measured as species richness (number of different taxa identified in each sample) in the intervention group compared to control group
Time frame: Baseline and 3 months after the start of the intervention
Effect of the multidomain intervention on the gut microbiota composition
Changes in gut microbiota in term of the most represented bacterial taxa (such as Faecalibacterium prausnitzii, Akkermansia muciniphila, Bifidobacterium spp, Lactobacillus spp; measured as average relative abundance) in the intervention group compared to control group
Time frame: Baseline and 3 months after the start of the intervention
Effect of the multidomain intervention on the gut microbiota composition
Changes in gut microbiota in terms of gene or transcript counts (measured as counts) in the intervention group compared to control group
Time frame: Baseline and 3 months after the start of the intervention
Feasibility of the multidomain intervention
Number of drop out (number) in the intervention group compared to control group
Time frame: At the end of the intervention (6 months after the start)
Effect of the multidomain intervention on the gut microbiota composition
Changes in gut microbiota biodiversity measured as species richness (number of different taxa identified in each sample) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on the gut microbiota composition
Changes in gut microbiota in terms of gene or transcript counts (measured as counts) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on the gut microbiota composition
Changes in gut microbiota in term of the most represented bacterial taxa (such as Faecalibacterium prausnitzii, Akkermansia muciniphila, Bifidobacterium spp, Lactobacillus spp; measured as average relative abundance) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on specific biomarkers
Changes in cholesterol (measured in mg/dl) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on specific biomarkers
Changes in triglycerides (measured in mg/dL) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on specific biomarkers
Changes in blood glucose (measured in mg/dL) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on specific biomarkers
Changes in vitamin D (measured in nmol/L) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on specific biomarkers
Changes in transferrin (measured in mg/dL) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on specific biomarkers
Changes in albumin (measured in g/dL) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on specific biomarkers
Changes in FT3 (measured in pg/mL) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on specific biomarkers
Changes in FT4 (measured in ng/dL) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on specific biomarkers of aging
Changes in IL-6 (measured in pg/mL) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on specific biomarkers of aging
Changes in BDNF (measured in ng/ml) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on specific biomarkers of aging
Changes in s-RAGE (measured in pg/mL) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on specific biomarkers of aging
Changes in irisin (measured in ng/ml) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on specific biomarkers of aging
Changes in IGF1 (measured in ng/mL) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on specific biomarkers of aging
Changes in ghrelin (measured in pg/mL) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on the nutritional status
Changes in Mini Nutritional Assessment (MNA, score 0-30, a higher score indicates a better outcome) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on anthropometric status and body composition
Changes in body mass index (BMI, with weight measured in kg and height measured in m combined to report BMI in kg/m\^2) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on anthropometric status and body composition
Changes in waist circumference (measured in cm) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on anthropometric status and body composition
Changes in calf circumference (measured in cm) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on anthropometric status and body composition
Changes in mid-upper arm circumference (measured in cm) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on upper limb strength
Changes in upper limb strength evaluated with electronic hand dynamometers (measured in kg) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on general and domain-specific cognitive functioning
Changes in the Addenbrooke's Cognitive Examination (ACE-R, minimum 0, maximum 10, a higher score indicate a better outcome) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on physical performance
Changes in the Short Physical Performance Battery (SPPB, minimum 0, maximum 12, a higher score indicates a better outcome) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on psychological health
Changes in the Geriatric Depression Scale (GDS, minimum score 0, maximum score 30, a higher score indicates a worse outcome) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on psychological health
Changes in the Perceived Stress Scale (PSS, minimum score 0, maximum score 40, a higher score indicates worse outcome) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on psychological health
Changes in the Depression Anxiety Stress Scale (DASS-21, minimum score 0, maximum score 63, a higher score indicates worse outcome) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on quality of life
Changes in the World Health Organization Quality of Life Scale (WHOQOL-BREF Physical Health, minimum score 0, maximum score 100, a higher score represents a better outcome) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on quality of life
Changes in the World Health Organization Quality of Life Scale (WHOQOL-BREF Psychological Health, minimum score 0, maximum score 100, a higher score represents a better outcome) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on quality of life
Changes in the World Health Organization Quality of Life Scale (WHOQOL-BREF Social Relationships, minimum score 0, maximum score 100, a higher score represents a better outcome) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on quality of life
Changes in the World Health Organization Quality of Life Scale (WHOQOL-BREF Environment, minimum score 0, maximum score 100, a higher score represents a better outcome) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on quality of life
Changes in the World Health Organization Quality of Life Scale (WHOQOL-BREF Quality of Life, minimum score 0, maximum score 5, a higher score represents a better outcome) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on quality of life
Changes in the World Health Organization Quality of Life Scale (WHOQOL-BREF Health Satisfaction, minimum score 0, maximum score 5, a higher score represents a better outcome) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on sleep quality
Changes in the Pittsburgh Sleep Quality Index (PSQI, minimum score 0, maximum score 21, a higher score indicates a worse outcome) in the intervention group compared to control group
Time frame: Baseline, 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on the number of hospitalization
Incidence (number) of hospitalizations during follow-up in the intervention group compared to control group
Time frame: 6 and 9 months after the start of the intervention
Effect of the multidomain intervention on the number of falls
Incidence (number) of falls during follow-up in the intervention group compared to control group
Time frame: 6 and 9 months after the start of the intervention
Plan to share: No
Ran from Feb 2025 to primary completion in Dec 2025, 10 months.
Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's 10 months is below that.
Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituto di Neuroscienze Consiglio Nazionale delle Ricerche